MedTrace Logo

Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes

NCT03396341 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 806

Last updated 2026-05-19

No results posted yet for this study

Summary

The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.

Conditions

  • Genetic Testing
  • BRCA1/2

Interventions

OTHER

Salvia sample

salvia sample

BEHAVIORAL

Questionnaires

Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system

OTHER

Buccal swab sample

Buccal swab sample

Sponsors & Collaborators

Principal Investigators

  • Jada Hamilton, PhD, MPH · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
25 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-04
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03396341 on ClinicalTrials.gov